Search results
225 Results for 'Donald E. Ingber'
- Technologies (17)
- Team (0)
- News (152)
- Events (15)
- Multimedia (41)
- Publications (0)
- Jobs (0)
Technologies 17
-
OMNIVAX: Broadly Deployable Infection Vaccine Platform
Infectious diseases pose one of the greatest threats to public health, and vaccination campaigns with broad population coverage – arguably the most powerful strategy for preventing, controlling, and treating infectious diseases – have eradicated or significantly reduced the risk of contracting diseases such as smallpox, measles, polio, and tetanus. However, there is a constant need for... -
Using Systems Biology to Find and Test New Drugs Faster
The pharmaceutical industry is infamous for big numbers: it takes 10-15 years and can cost over $2 billion to bring a new drug from the lab to the market. Up to 6 of those years and $1 billion are spent in laborious preclinical trials to identify and validate new potential drug compounds, and much of... -
eRapid: Multiplexed Electrochemical Sensors for Fast, Accurate, Portable Diagnostics
Handheld electrochemical sensors have revolutionized at-home medical testing for diabetics, but they have not yet been successfully applied to diagnosing other conditions. These sensors are based on the activity of an enzyme, and there are only a limited number of enzymes that can be used to detect biomarkers of human disease. An alternative, much more... -
Brain Targeting Program: Shuttles for Brain Delivery of Therapeutics and Diagnostics
In its Brain Targeting Program, a Wyss team led by Founding Director Donald Ingber, M.D., Ph.D. and Staff Program Lead James Gorman, M.D., Ph.D. is developing improved approaches to target drugs and diagnostics to the brain. Leveraging the human blood-brain barrier (BBB) Chip technology developed by Ingber’s team, combined with advanced antibody R&D capabilities, the... -
DNA Data Storage
The genetic material DNA has garnered considerable interest as a medium for digital information storage because its density and durability are superior to those of existing silicon-based storage media. For example, DNA is at least 1000-fold more dense than the most compact solid-state hard drive and at least 300-fold more durable than the most stable... -
AquaPulse: Portable Off-the-Grid Water Purification
Globally, more than 2 billion people are forced to use a drinking water source that is contaminated with bacteria, parasites, and other pathogens, and an estimated 502,000 people die each year from diarrhea as a result of unsafe water. While a majority of the world has access to improved water sources, many are often contaminated;...
News 152
Events 15
-
Jun 23, 2020, 5:00pm - 6:00pmLecture
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
Don’t miss these thought-provoking conversations with local leaders in the race to fight COVID-19. Next Tuesday, hear firsthand from Donald E. Ingber, M.D., Ph.D how the Wyss Institute was able to quickly pivot and refocus their unique engineering capabilities on much-needed diagnostic, therapeutic, and vaccine solutions. Free and open to public -
Jun 18, 2020, 4:00pm - 5:30pmLecture
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
The Rice University Department of Bioengineering has organized a webinar series open to all members of the bioengineering and biomedical research community. Wyss Founding Director Don Ingber will be one of the speakers at the June 18 event entitled, “Engineering Physiologically Relevant Tissues.” As the COVID-19 pandemic unfolds across the globe, these unprecedented times have... Free and open to public -
Mar 30, 2020, 8:00am - 5:00pmSymposium
- Add to Calendar
- iCalendar
- Google Calendar
- Outlook
The Harvard Stem Cell Institute presents the Annual Developmental & Regenerative Biology Program Symposium. Wyss Founding Director Don Ingber will be one of the speakers. The other speakers will be Hanna Mikkola (UCLA), Mark Fishman (HSCI), and Amy Shyer (Rockefeller). Free and open to public
Multimedia 41
-
Video/AnimationOMNIVAX: Infection Vaccine PlatformThis video explains how OMNIVAX – an immuno-material-based vaccine technology can be used to rapidly create injectable vaccines against diverse viral and bacterial pathogens, and how the platform is used by the team to develop a vaccine against recurring urinary tract infections (UTIs) in their lead human application. Credit: Wyss Institute at Harvard University. -
Video/AnimationBeating Back the Coronavirus: FDA-Approved Drug Repurposing PipelineWith the goal of rapidly repurposing FDA-approved drugs to treat COVID-19, the Wyss Institute is collaborating with the Frieman Lab at the University of Maryland Medical School and the tenOever Lab at the Icahn School of Medicine at Mount Sinai to establish a multidisciplinary pipeline that can rapidly predict, test, and validate potential treatments. Credit:... -
Audio/PodcastTalking Techniques: Donald Ingber: How COVID-19 is changing conservatism in life sciences (Part 2)Following on from part 1 of this interview with the Founding Director of the Wyss Institute, Donald Ingber discusses the reasons he thinks organ-on-a-chip technologies are yet to be widely implemented in research. Expanding on elements of conservatism rooted in certain aspects of the life sciences, Donald explores how the scientific response to the current COVID-19 pandemic is challenging entrenched... -
Audio/PodcastTalking Techniques: COVID-19, Organ Chips and the Wyss Institute (Part 1)In the first installment of this two-part episode with Donald Ingber, Founding Director of the Wyss Institute (MA, USA), we discuss his invention of organ-on-a-chip technology, how he is utilizing them in the fight against COVID-19 and the Wyss Institute’s response to the pandemic. Donald touches on the performance of the much-discussed chloroquine in his... -
Video/AnimationCreating Scientific Marvels that are Works of ArtDuring his TEDx talk, Don Ingber shares his personal path from an ‘Aha’ moment in an undergraduate art class that led to his discovery of how living cells are constructed to his most recent breakthrough – a Human Body-On-Chips – which promises to replace animal testing and advance personalized medicine. Don’s work breaks down boundaries... -
Video/AnimationCogniXense: Speeding Up Treatments for Rare DiseasesAt the Wyss Institute, we are tackling Rett syndrome, a rare disease that affects 1 out of 9,000 children, by developing a scalable model for neurodevelopmental and cognitive diseases. This model can test drugs to see which will improve memory, learning, and behavior, with the end goal of finding effective therapies. Credit: Wyss Institute at...